Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.65 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.58 |
| ▸ | RXRA | P19793 | 1/20 | 0.58 |
| ▸ | RXRB | P28702 | 1/20 | 0.58 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.49 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | MAOB | P27338 | 5/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22275947 | 0.87 | APP (0.82) | APPNR4A2RXRARXRBNR4A1 | |
| SCHEMBL4650257 | 0.83 | APP (0.45) | APPNR4A2RXRARXRBRAB9A | |
| SCHEMBL697164 | 0.82 | MAOB (0.65) | MAOB | |
| SCHEMBL12264541 | 0.81 | APP (0.69) | APPNR4A2RXRARXRBNR4A1 | |
| SCHEMBL1702727 | 0.81 | APP (0.74) | APPNR4A2RXRARXRBNR4A1 | |
| SCHEMBL6154800 | 0.80 | APP (0.54) | APPNR4A2RXRARXRBNR4A1 | |
| SCHEMBL13439792 | 0.80 | APP (0.72) | APPNR4A2RXRARXRBRAB9A | |
| SCHEMBL13761551 | 0.80 | APP (0.72) | APPNR4A2RXRARXRBNR4A1 | |
| SCHEMBL13929695 | 0.80 | APP (0.72) | APPNR4A2RXRARXRBNR4A1 | |
| SCHEMBL543113 | 0.79 | MAOB (0.54) | APPRAB9ANPC1MAOBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9567355-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2017-02-14 | — | — | US | disclosed |
| US-20160355530-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. | 2016-12-08 | — | — | US | disclosed |
| US-9453007-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20160002213-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. | 2016-01-07 | — | — | US | disclosed |
| US-9173887-B2 | Hepatitis C inhibitors and uses thereof | ABBVIE INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140038919-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | ABBVIE INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-6610731-B2 | Antiinflammatory | BRISTOL-MYERS SQUIBB COMPANY | 2003-08-26 | — | — | US | disclosed |
| US-6403632-B1 | CYCLIC AMIDE DERIVATIVE | BRISTOL MYERS SQUIBB PHARMA CO (US) | 2002-06-11 | — | — | US | disclosed |
| US-5814646-A | TREATING THE PROGRESSION OF ALZHEIMER'S DISEASE, BRAIN DISORDERS | ELI LILLY AND COMPANY (US) | 1998-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160002213-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | APP 4360/4885NR4A2 4383/4885RXRA 1542/4885 |
| US-20140038919-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | APP 4360/4885NR4A2 4383/4885RXRA 1542/4885 |
| US-20160355530-A1 | HEPATITIS C INHIBITORS AND USES THEREOF | HAVCR2, HCCS, SLC10A1 | APP 4360/4885NR4A2 4383/4885RXRA 1542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.